|
Not only do we believe that Nuvilex (OTCQB – NVLX) is attractive at current levels but we believe that the stock will make another big run this spring based on fundamental, catalytic, and technical reasons.
...
A series of recent landmark events in the marijuana and medical marijuana space, along with a revaluation of biotechs, are set to serve as triggers prompting the accumulation and rise of Nuvilex’s stock ...
In the 21st century, certain initiatives have moved so far and so fast that they have tend to take on a life of their own. This is clearly the case with marijuana early 2014, now that the nation has overwhelmingly ...
According to the latest estimates released recently by the International Diabetes Federation (IDF), the number of people diagnosed with diabetes worldwide is soaring. Moreover, with deaths occurring at ...
Emerging biotech stocks typically are one-trick ponies which is one major reason why the likelihood of success is elusive and rare.
Investment and Company Research Opportunity Research ...
Yesterday’s landmark announcement by Nuvilex Inc. (OTCQB – NVLX) likely assures that the company will receive a future boost in its overall valuation. Nuvilex has acquired the exclusive worldwide rights ...
In a year where there have been quite a few misfires in the small biotech world, Nuvilex, Inc. (OTCQB – NVLX - $0.139 – Spec Buy) is a shining star.
Investment and Company Research Opportunity ...
Savvy traders and followers of Nuvilex, Inc. (OTCQB – NVLX - $0.114 – Spec Buy), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases can sense ...
In the near term, the pending 3Q13 financial report from Celgene (NASDAQ - CELG), which is due later this week, will place further attention on the pancreatic cancer treatment sector, and by association, ...
Currently, there are only 3 drugs approved for treatment of the disease. But, there are some catalysts up ahead which could drive this group of small cap biotech stocks meaningfully higher.
Investment ...
The fourth quarter of the year is typically a good one for micro cap stocks due to seasonal and macro issues and this year should be no different. For Nuvilex, Inc. (OTCQB – NVLX - $0.12 – Spec Buy) shareholders, ...
For investors seeking a well-positioned mid-late stage biotechnology company, one may not need to go any further than Nuvilex, Inc. (OTCQB – NVLX - $0.135 – Spec Buy). The Company has nearly all of the ...
With a great deal of experience in protocol design, Nuvilex management is well on its way to designing, compiling, and completing the necessary steps in order to move forward as quickly as possible.
Investment ...
The Company released news that should have been received by investors as its most significant event to date, excluding the acquisition of rights to the ground-breaking live-cell encapsulation technology ...
There is a buzz in certain biotech circles regarding the high value of encapsulation technologies and targeted therapy delivery platforms. For example, Bind Therapeutics, Inc., a high profile biotech that ...
One of the key catalysts in the near term for Nuvilex Inc. (OTCQB – NVLX - $0.146 – Spec Buy) is the establishment of a GMP (Good Manufacturing Practices) facility. The facility will be used to encapsulate ...
This partnership is a critical step for Nuvilex and confirms the Company’s status as a well-regarded player in the cancer treatment development segment.
Investment and Company Research Opportunity ...
While it is natural for investors to interpret the value a larger firm would have on Nuvilex, the value proposition that Nuvilex offers a larger firm should not be discounted either.
Investment ...
With major milestones achieved in just a few months and several more ahead, plus trading at a big discount to its peers, what more could an investor ask for in a stock?
...
With big check marks alongside these hurdles, Nuvilex has the potential to become one of biotech’s major players, given its roadmap in the treatment of cancer and diabetes. As a result, the Company’s stock ...
It is not uncommon for entrepreneurial or young firms to engage in various strategies or iterations through the lifecycle of the Firm. In some cases, legacy business segments, while smaller or seemingly ...
When events in progress take longer to complete than originally expected, investors often forget that upcoming events may be as important or even more critical than previous milestones. For longtime investors ...
Lost in the dog days of August is the remarkable performance of Nuvilex, Inc. (OTCQB – NVLX) relative to the market and some of its key peers. Over the past ten days, while biotech stocks have largely ...
Nuvilex is moving yet another step closer toward introducing a game-changing multi-disease treatment platform that is potentially worth billions in annual sales.
Investment and ...
Once or perhaps twice a year, something happens to a stock that smacks it down on strong volume. These events are usually triggered by misunderstandings or disinformation
Investment and Company ...
Given the substantial costs to administer and conduct clinical trials exclusively in the U.S., it is likely that Nuvilex, Inc. (OTCQB – NVLX- $0.165 – Spec Buy) will elect to turn to overseas locations ...
When one lifts up the hood, one realizes that a sleeping giant in the form of highly successful animal trials to treat mammary tumors may emerge as a real blockbuster for Nuvilex.
Investment ...
Let’s face it, the Company gets no respect. That is all about to change. In fact, we predict that Nuvilex will ultimately turn from Rodney Dangerfield into Cinderella.
Investment and Company ...
Nuvilex’s just released shareholder update indicates that recent and pending milestones set the stage for a big 2014 for the Company.
Investment and Company Research
...
Considering the success of some of the programs in Israel in treating cancer patients with cannabis, Nuvilex Inc.’s (OTCQB – NVLX - $0.16 – Spec Buy) subsidiary, Medical Marijuana Sciences, Inc. may elect ...
Based on recent grants, , Nuvilex appears well positioned to be eligible to receive research lucrative grants or funding from other partner firms seeking to study the efficacy of live-cell encapsulation-based ...
Recent events and future milestones serve to benefit Nuvilex as the stars align for management and its shareholders.
Investment and Company Research Opportunity Research MICROCAP HOT TOPICS ...
Whether one is referring to high-profile nanomedicine-based firms or pre-clinical university research, the fact that drug delivery is at the forefront of the fight against cancer bodes well for Nuvilex, ...
By taking a very slow and steady approach, and focusing on the most critical piece of the acquisition (exclusive license) instead of becoming too big too soon (by acquiring the entity), management executed ...
This tactical acquisition gives NVLX everything it wanted, plus lower operating costs, and sets it up for 3rd party funding and clinical trials. Moreover, the pricing of the deal was 10% higher than the ...
The medical marijuana industry received a major boost recently at the annual United States Conference of Mayors. A unanimous and bipartisan resolution urging the federal government to let states decide ...
The Company’s 2 clinical trials clearly illustrate the great potential efficacy in using encapsulated cells with a pro-drug as a targeting device for the treatment of solid pancreatic and mammary tumors, ...
Considering that Nuvilex likely has much greater experience in successfully conducting oncology clinical trials than any other player in the space, it is anecdotal evidence such as the San Francisco study ...
Although Nuvilex Inc. (OTCQB – NVLX - $0.11 – Spec Buy) is noted for its pancreatic cancer treatment studies, it may be that a combination of its canine mammary cancer trial and medical marijuana research ...
If Nuvilex were to generate its previous results in a late Phase II or Phase III trial, the Company would likely be the oncology treatment story of the year. For those keeping score, Celgene’s lauded drug ...
|
||
|
|
||